In conclusion, we successfully achieved somatic genome editing of Bap1, Pbrm1, and to some extent Setd2 in two novel GEMMs for early ccRCC through use of an inducible CRISPR-Cas9 system. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.